Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA repair gene expression in NSCLC patients treated with standard chemotherapy
2008-000936-42Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- May 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of docetaxel, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Correlation between DNA repair gene expression levels and response to standard chemotherapy. Started May 2008; status: active.
02
Drugs
docetaxelgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on 2008-000936-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000936-42.